Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry

(2011) Markus Christmann et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status

(2011) Ann I. McCormack et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Pituitary Carcinoma with Malignant Growth from First Presentation and Fulminant Clinical Course—Case Report and Review of the Literature

(2011) Katarzyna Dudziak et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas

(2011) Fateme Salehi et al.   JOURNAL OF NEURO-ONCOLOGY

Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity

(2011) Harsha Prasada Lashkari et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review

(2011) Lorenzo Curtò et al.   TheScientificWorldJOURNAL

Treatment of pituitary neoplasms with temozolomide

(2010) Luis V. Syro et al.   CANCER

Dose-dense temozolomide regimens

(2010) Bart Neyns et al.   CANCER

Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis

(2010) Françoise Galland et al.   ENDOCRINE-RELATED CANCER

Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases

(2010) Marco Losa et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases

(2010) H. Bode et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Prognostic Factors in Prolactin Pituitary Tumors: Clinical, Histological, and Molecular Data from a Series of 94 Patients with a Long Postoperative Follow-Up

(2010) Gérald Raverot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression

(2010) Zachary M. Bush et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience

(2010) Gérald Raverot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Atypical pituitary adenomas: incidence, clinical characteristics, and implications

(2010) Gabriel Zada et al.   JOURNAL OF NEUROSURGERY

Proliferation markers of human pituitary tumors: Contribution of a genome-wide transcriptome approach

(2010) Anne Wierinckx et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Temozolomide for corticotroph pituitary adenomas refractory to standard therapy

(2010) Troy H. Dillard et al.   Pituitary

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation

(2009) Philippe Metellus et al.   CANCER

O6-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas

(2009) Georg Widhalm et al.   CANCER

Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)

(2009) Alberto Fernandez et al.   CLINICAL ENDOCRINOLOGY

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

(2009) C Hagen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A novel use of temozolomide in a patient with malignant prolactinoma

(2009) Stephen Byrne et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas?

(2009) Mustafa Khasraw et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

(2009) Lucie Karayan-Tapon et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

THE CORRELATION AND PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION AND MGMT PROTEIN IN GLIOBLASTOMAS

(2009) Van Thang Cao et al.   NEUROSURGERY

USE OF TEMOZOLOMIDE IN AGGRESSIVE PITUITARY TUMORS

(2009) Safraz Mohammed et al.   NEUROSURGERY

Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor

(2009) Marie S. Thearle et al.   Pituitary

Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours

(2008) Ann I. McCormack et al.   CLINICAL ENDOCRINOLOGY

Treatment of Nelson's syndrome with temozolomide

(2008) V J Moyes et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

New (alternative) temozolomide regimens for the treatment of glioma

(2008) Wolfgang Wick et al.   NEURO-ONCOLOGY

Management of aggressive pituitary adenomas: current treatment strategies

(2008) Michael Buchfelder   Pituitary